Tonix Pharmaceuticals (TNXP)
(Delayed Data from NSDQ)
$0.18 USD
+0.01 (7.25%)
Updated May 3, 2024 04:00 PM ET
After-Market: $0.18 0.00 (-1.91%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMTonix Pharmaceuticals Holding Corp. (TNXP) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$2.97 | $6.00 | $1.40 | 1,647.06% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Tonix Pharmaceuticals Holding Corp. comes to $2.97. The forecasts range from a low of $1.40 to a high of $6.00. The average price target represents an increase of 1% from the last closing price of $0.17.
Analyst Price Targets (3 )
Broker Rating
Tonix Pharmaceuticals Holding Corp. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the two recommendations deriving the current ABR, two are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 3 | 3 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/11/2024 | Noble Financial | Robert Leboyer | Strong Buy | Strong Buy |
3/15/2024 | Alliance Global Partners | James Molloy | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 2 |
Average Target Price | $2.97 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 98 of 252 |
Current Quarter EPS Est: | -0.52 |